TenQ · fact sheet · filings current to · price as of
Pfizer (PFE)
A mixed picture - strengths and real weaknesses - 15 of 29 checks passed.
Latest close : $28.45, -1.2% on the day; -2.0% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $28.45 |
| Market cap | $162.2B |
| 52-week range | $22.05 - $29.02 |
| P/E | 37.5x |
| P/E, own 11-year median | 15.7x |
| P/S | 2.5x |
| Free cash flow yield | 6.8% |
| Dividend yield | - |
| Revenue (TTM) | $63.7B |
| Net income (TTM) | $4.3B |
| Free cash flow (TTM) | $11.0B |
| Gross margin | 73.2% |
| Operating margin | - |
| Return on equity | 5.1% |
| Revenue growth (1y) | -0.2% |
| Revenue CAGR (3y) | -12.0% |
| Debt / equity | 0.74x |
| Cash & short-term investments | $28.7B |
| Shares outstanding | 5,699.7m (cover page of the latest filing, 2026-07-29) |
The score: 15 of 29 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is PFE stock cheap or expensive right now?
Value · 1 of 4 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is Pfizer still growing?
Growth · 1 of 6 checks passed. Growth is weak or inconsistent - the trend, not the story, is the problem. chapter →
Does Pfizer make real money?
Quality · 3 of 4 checks passed. A solidly profitable business, though not exceptional against its sector. chapter →
Can Pfizer survive a bad year?
Health · 3 of 5 checks passed. Financially sound overall, with one or two things worth watching. chapter →
What does Pfizer hand back to shareholders?
Shareholder returns · 1 of 4 checks passed. PFE returns nothing to owners yet - every dollar stays in the business. chapter →
Which way is PFE trending?
Trend analysis · 6 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling PFE?
Open-market buys: $3M · sells: $134,661, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.